#United States #New York #Pomerantz Law #SEC Investigations #argenx SE

Pomerantz Law Firm Investigates Argenx SE Amid Investor Concerns

On October 29, 2026, Pomerantz LLP announced an investigation concerning Argenx SE (NASDAQ: ARGX), focusing on potential claims from its investors. This scrutiny comes in light of serious allegations that the company and its executives might have participated in securities fraud and other illegal business practices.

The firm requests affected investors, particularly those impacted by significant stock declines, to reach out to them for potential involvement in a class action lawsuit.

Background of Argenx SE

Argenx SE is a global biotechnology company known for developing innovative therapies to treat serious autoimmune diseases. One of its most anticipated contributions was the Phase 3 UNITY study focusing on efgartigimod, which was aimed at treating moderate to severe Sjögren's disease. However, the company recently made headlines for all the wrong reasons.

Discontinuation of the UNITY Study

On October 8, 2026, Argenx announced via a press release that it would be discontinuing the Phase 3 UNITY study. This decision was made based on a recommendation from an Independent Data Monitoring Committee (IDMC) after an interim analysis concluded that the study was unlikely to meet its primary endpoint. The discontinuation was a significant setback, raising questions about the company's pipeline and future prospects in the biotech landscape.

This news triggered an immediate reaction in the stock market, where shares of Argenx SE plummeted by $109.81 per share, representing a decline of 11.83%. Following the announcement, the stock closed at $818.63, igniting investor panic and prompting concerns over the integrity of the company's management and operational strategies.

Potential Implications for Investors

The investigation by Pomerantz LLP highlights the potential risks involved in investing in pharmaceutical and biotech companies, particularly when substantial operational changes occur. The firm's history as a leader in class action lawsuits underscores the seriousness with which they treat these allegations. Founded by legal pioneer Abraham L. Pomerantz, the firm has a legacy of advocating for victims of corporate misconduct, and their current probe signals their commitment to ensuring investor rights are upheld.

How to Get Involved

Investors who believe they have suffered from losses related to Argenx SE’s recent downturn are encouraged to promptly contact Pomerantz LLP's Danielle Peyton at the provided contact information. Investors should be aware of their rights regarding securities fraud and should consider exploring their options in possibly joining a class action suit.

Conclusion

The investigation into Argenx SE serves as a compelling reminder of the volatility that can exist in the biotech market, especially in relation to clinical trial results and corporate governance. As this situation unfolds, investors remain on high alert, monitoring further developments. Pomerantz LLP is prepared to take action to protect the interests of investors, ensuring they have the opportunity to seek justice for any potential securities fraud they have endured.

Stay informed on the outcomes of this investigation and other similar news by keeping an eye on updates from Pomerantz LLP as they continue their work in corporate and securities law.